Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241708 · ClinicalTrials.gov registry record · Phase 3
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
A Phase 3 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 148
- Enrollment target
NCT01241708 is a Phase 3 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 148 participants.
The verdict
NCT01241708, a Phase 3 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 148 participants
- Enrollment target
Study Summary
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant recipients worldwide for the same or similar disorders.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2010-04-08 |
| Est. Completion | 2023-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01241708
The ClinicalTrials.gov registry entry for NCT01241708 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT01241708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01241708 about?
NCT01241708 is a clinical study titled "Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma". High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant recipients worldwide for the same or similar disorders.
What is the current status of trial NCT01241708?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2010-04-08. Estimated completion is 2023-07-15.
What interventions are being tested in trial NCT01241708?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01241708?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.